Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RB1 | P06400 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834331 | 1.00 | MEN1 (0.53) | MEN1KMT2AHPGDHSD17B10TP53 | |
| SCHEMBL1905530 | 1.00 | MEN1 (0.53) | MEN1KMT2AHPGDHSD17B10TP53 | |
| SCHEMBL29655380 | 1.00 | MEN1 (0.53) | MEN1KMT2AHPGDHSD17B10TP53 | |
| SCHEMBL29991881 | 0.91 | RB1 (0.58) | MEN1KMT2AHPGDHSD17B10TP53 | |
| SCHEMBL29991664 | 0.91 | RB1 (0.58) | MEN1KMT2AHPGDHSD17B10TP53 | |
| SCHEMBL29991670 | 0.91 | RB1 (0.58) | MEN1KMT2AHPGDHSD17B10TP53 | |
| SCHEMBL24408182 | 0.84 | JAK2 (0.43) | MEN1KMT2AHTR1AHTR1DHTR1B | |
| SCHEMBL1335387 | 0.84 | HTR1A (0.43) | MEN1KMT2AHTR1AHTR1DHTR1B | |
| SCHEMBL1903598 | 0.84 | HTR1A (0.51) | MEN1KMT2AHTR1AHTR1DHTR1B | |
| SCHEMBL14624292 | 0.84 | HTR1B (0.53) | MEN1KMT2AHTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110831600-A | Indole AHR inhibitors and uses thereof | 金恩医疗公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-9296689-B2 | Substituted isoindoline-1,3-dione derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2051962-B1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2316824-A1 | (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | MEN1 4015/4885KMT2A 3683/4885HPGD 95/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | MEN1 4767/4885KMT2A 622/4885HPGD 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.